Xcellon Biologics offers CRDMO services for antibody discovery, linker-payload screening, ADC functional characterization, and in vivo pharmacology support across four phases of ADC and complex biologics discovery.

Our Vision: To build one of the nation’s premier CRDMOs for bioconjugates and complex biologics, advancing U.S. biomanufacturing and enabling innovators to bring next-generation therapies from discovery to clinical supply. Our Mission: To deliver integrated, flexible, high-quality solutions for the development and manufacturing of complex biologics. By reducing handoffs and maintaining scientific continuity throughout development, we help biotechnology innovators accelerate the path of transformative therapies from discovery to patients. Our Company: Xcellon Biologics is a U.S.-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, including antibody-drug conjugates (ADCs), bispecific antibodies, and T-cell engagers. Our integrated capabilities span cell line development, antibody development and manufacturing, bioconjugation development and manufacturing, process development, analytical characterization, GMP manufacturing, and clinical supply. By bringing these capabilities together under one organization, Xcellon provides a single, trusted partner to efficiently advance next-generation biologics from discovery through clinical supply.